



ST.JUDE-**viva** Survivorship  
SERIES 3

Webinar #8:  
**OSTEOSARCOMA**

14th Jun 2024 | 8:00PM – 9:30PM (GST +8 | Singapore Time)

<b>Program Name:</b>	St. Jude-VIVA Survivorship Series 3 Webinar #8
<b>Event Date:</b>	Friday, 14th June 2024
<b>Event Time:</b>	8:00pm – 9:30pm (Singapore Time)

## Programme Synopsis

### Lecture Title:

#### Osteosarcoma

*Dr Michael Bishop, St. Jude Children's Research Hospital*

Osteosarcoma is the most common bone tumor of childhood and adolescence. Patients receive multimodal therapy with intensive chemotherapy and aggressive surgery, and are at risk for a number of chronic health conditions. This presentation will review the common late effects associated with therapy for osteosarcoma.



## Presenter Bio

**Dr Michael Bishop**

**Assistant Member, St. Jude Faculty  
St. Jude Children's Research Hospital  
USA**

Dr. Michael W. Bishop is an Assistant Member in the Department of Oncology at St. Jude Children's Research Hospital. His primary clinical and research interests are the treatment of bone and soft tissue sarcomas and clinical trial development. Dr. Bishop is currently the study chair for the Children's Oncology Group trial AOST2032, a feasibility and phase 2/3 study of the addition of a tyrosine kinase inhibitor to standard chemotherapy for newly diagnosed osteosarcoma.



## Organising Chair/Moderator

**Dr Melissa Hudson**

**Member, St. Jude Faculty  
Director, Cancer Survivorship Division  
Co-Leader, Cancer Control & Survivorship Program  
The Charles E. Williams Endowed Chair of Oncology-Cancer  
Survivorship  
St. Jude Children's Research Hospital  
USA**